Professor Ih-Jen Su, Southern Taiwan University of Science and Technology


The self-production rate of human vaccines (8%) in Taiwan is significantly lower than that in other countries (US 100%, Japan 59%, and South Korea 38%). Moreover, Taiwan may not be able to obtain vaccines against emerging infectious diseases during pandemics, such as the 2009 pandemic influenza H1N1). Therefore, there is an urgent need to convene an advisory committee to combat the threats by addressing the following three issues: 1) advance pricing arrangement (APA) mechanism for pandemic influenza vaccines, 2) development of emerging infectious disease vaccines, 3) planningof national vaccine policies, and 4) development of COVID-19 vaccines.